home / stock / achv / achv news

ACHV News and Press, Achieve Life Sciences Inc. From 09/09/21

Stock Information
Company Name: Achieve Life Sciences Inc.
Stock Symbol: ACHV
Market: NASDAQ
Website: achievelifesciences.com
Menu
ACHV ACHV Quote ACHV Short ACHV News ACHV Articles ACHV Message Board
Get ACHV Alerts

News, Short Squeeze, Breakout and More Instantly...
ACHV - Achieve Life Sciences to Participate in Two Upcoming Investor Conferences

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 9, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that Jo...
ACHV - Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the ...

ACHV - Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2021 Results - Earnings Call Transcript

Achieve Life Sciences, Inc. (ACHV) Q2 2021 Earnings Conference Call August 12, 2021, 16:30 ET Company Participants Jaime Xinos - EVP, Commercial John Bencich - CEO & Director Jerry Wan - Principal Accounting Officer Cindy Jacobs - President, Chief Medical Officer & Director Conference...

ACHV - Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 12, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second qu...
ACHV - Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that th...

ACHV - Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 3, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it ...

ACHV - NIH nods Achieve Life Sciences for evaluation of cytisinicline in cessation of nicotine E-cigarette use

Drazen_/E+ via Getty Images Achieve Life Sciences ([[ACHV]]) awarded a grant from the National Institute on Drug Abuse of the National Institutes of Health (or NIH) to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use. The initial grant to commenc...
ACHV - Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / July 22, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has...

ACHV - Achieve Life Sciences completes target enrollment in late-stage smoking cessation study

Achieve Life Sciences (ACHV) announces that it has reached target enrollment of 750 adult smokers in the company's late-stage smoking cessation study of cytisinicline.The trial is designed to evaluate the smoking cessation effectiveness, safety, and tolerability of 3 mg cytisinicline taken th...

ACHV - Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline

ORCA-2 Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United States SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / June 29, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceuti...
Previous 10 Next 10